Home > Research > Publications & Outputs > Associating CYP2A6 structural variants with ova...

Research

Electronic data

  • oc_paper_text_clean_oct27_AL

    Accepted author manuscript, 263 KB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

Text available via DOI:

Keywords

View graph of relations

Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension. / Langlois, Alec W. R.; Pouget, Jennie G.; Knight, Jo et al.
In: European Journal of Human Genetics, Vol. 32, No. 3, 01.03.2024, p. 357-360.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Langlois, AWR, Pouget, JG, Knight, J, Chenoweth, MJ & Tyndale, RF 2024, 'Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension', European Journal of Human Genetics, vol. 32, no. 3, pp. 357-360. https://doi.org/10.1038/s41431-023-01518-2

APA

Langlois, A. W. R., Pouget, J. G., Knight, J., Chenoweth, M. J., & Tyndale, R. F. (2024). Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension. European Journal of Human Genetics, 32(3), 357-360. https://doi.org/10.1038/s41431-023-01518-2

Vancouver

Langlois AWR, Pouget JG, Knight J, Chenoweth MJ, Tyndale RF. Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension. European Journal of Human Genetics. 2024 Mar 1;32(3):357-360. Epub 2023 Dec 14. doi: 10.1038/s41431-023-01518-2

Author

Langlois, Alec W. R. ; Pouget, Jennie G. ; Knight, Jo et al. / Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank : replication and extension. In: European Journal of Human Genetics. 2024 ; Vol. 32, No. 3. pp. 357-360.

Bibtex

@article{b309ef1de5714dd79759cb92ff4788b2,
title = "Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension",
abstract = "CYP2A6 is a polymorphic enzyme that inactivates nicotine; structural variants (SVs) include gene deletions and hybrids with the neighboring pseudogene CYP2A7. Two studies found that CYP2A7 deletions were associated with ovarian cancer risk. Using their methodology, we aimed to characterize CYP2A6 SVs (which may be misidentified by prediction software as CYP2A7 SVs), then assess CYP2A6 SV-associated risk for ovarian cancer, and extend analyses to lung cancer. An updated reference panel was created to impute CYP2A6 SVs from UK Biobank array data. Logistic regression models analyzed the association between CYP2A6 SVs and cancer risk, adjusting for covariates. Software-predicted CYP2A7 deletions were concordant with known CYP2A6 SVs. Deleterious CYP2A6 SVs were not associated with ovarian cancer (OR = 1.06; 95% CI: 0.80-1.37; p = 0.7) but did reduce the risk of lung cancer (OR = 0.44; 95% CI: 0.29-0.64; p ",
keywords = "Genetics (clinical), Genetics",
author = "Langlois, {Alec W. R.} and Pouget, {Jennie G.} and Jo Knight and Chenoweth, {Meghan J.} and Tyndale, {Rachel F.}",
year = "2024",
month = mar,
day = "1",
doi = "10.1038/s41431-023-01518-2",
language = "English",
volume = "32",
pages = "357--360",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "3",

}

RIS

TY - JOUR

T1 - Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank

T2 - replication and extension

AU - Langlois, Alec W. R.

AU - Pouget, Jennie G.

AU - Knight, Jo

AU - Chenoweth, Meghan J.

AU - Tyndale, Rachel F.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - CYP2A6 is a polymorphic enzyme that inactivates nicotine; structural variants (SVs) include gene deletions and hybrids with the neighboring pseudogene CYP2A7. Two studies found that CYP2A7 deletions were associated with ovarian cancer risk. Using their methodology, we aimed to characterize CYP2A6 SVs (which may be misidentified by prediction software as CYP2A7 SVs), then assess CYP2A6 SV-associated risk for ovarian cancer, and extend analyses to lung cancer. An updated reference panel was created to impute CYP2A6 SVs from UK Biobank array data. Logistic regression models analyzed the association between CYP2A6 SVs and cancer risk, adjusting for covariates. Software-predicted CYP2A7 deletions were concordant with known CYP2A6 SVs. Deleterious CYP2A6 SVs were not associated with ovarian cancer (OR = 1.06; 95% CI: 0.80-1.37; p = 0.7) but did reduce the risk of lung cancer (OR = 0.44; 95% CI: 0.29-0.64; p 

AB - CYP2A6 is a polymorphic enzyme that inactivates nicotine; structural variants (SVs) include gene deletions and hybrids with the neighboring pseudogene CYP2A7. Two studies found that CYP2A7 deletions were associated with ovarian cancer risk. Using their methodology, we aimed to characterize CYP2A6 SVs (which may be misidentified by prediction software as CYP2A7 SVs), then assess CYP2A6 SV-associated risk for ovarian cancer, and extend analyses to lung cancer. An updated reference panel was created to impute CYP2A6 SVs from UK Biobank array data. Logistic regression models analyzed the association between CYP2A6 SVs and cancer risk, adjusting for covariates. Software-predicted CYP2A7 deletions were concordant with known CYP2A6 SVs. Deleterious CYP2A6 SVs were not associated with ovarian cancer (OR = 1.06; 95% CI: 0.80-1.37; p = 0.7) but did reduce the risk of lung cancer (OR = 0.44; 95% CI: 0.29-0.64; p 

KW - Genetics (clinical)

KW - Genetics

U2 - 10.1038/s41431-023-01518-2

DO - 10.1038/s41431-023-01518-2

M3 - Journal article

C2 - 38097766

VL - 32

SP - 357

EP - 360

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 3

ER -